Antecedent hypertension adversely affects mortality and heart failure after myocardial infarction (MI).
Introduction
Although antecedent hypertension is known to adversely affect mortality after acute myocardial infarction (MI) (1−4), whether (and in which patients) it also heightens the risk of developing heart failure is disputed (5−7). Furthermore, the potential interactions of antecedent hypertension with other predictors of postinfarction heart failure and poor prognosis are well known. Because hypertension induces structural changes within the left ventricle (8−10), we hypothesized that patients with antecedent hypertension would be more likely to develop left ventricular (LV) remodeling after MI. In the present study, therefore, we analyzed LV cavity and function by LV angiography after acute MI in patients with and without antecedent hypertension.
Methods

Patient Selection
Ninety-four patients presenting with a first acute MI who were treated with reperfusion therapy and attained a thrombolysis in myocardial infarction (TIMI) flow grade 3 within 12 h of their symptom onset were enrolled in this study. The diagnosis of acute MI was based on chest pain lasting > 30 min, ST segment elevation of > 0.2 mV in at least two contiguous ECG leads, and elevation of the serum creatine kinase (CK) level to greater than three times the upper limit of the normal range. Patients who had a history of previous MI, a TIMI grade of 3 at the time of initial angiography, an occurrence of re-infarction within 6 months, or restenosis of target vessels at the 6-month follow-up, and those with significant valvular heart disease were excluded. In addition, patients with a maximum serum CK less than 1,000 IU/l were also excluded. The maximum serum CK was defined as the peak value among those measured every 3 h after reperfusion therapy. Patients were categorized as having antecedent hypertension if this diagnosis was known by the patients to have been made by their family physician or after specialist referral, if the acute admission note indicated a history of hypertension and/or they were receiving antihypertensive medication. All patients received conventional drug therapy according to individual need, and such therapy remained the responsibility of the attending physician. Patients with hypertension were started on antihypertensive drug treatment immediately after admission. In patients with hypertension, systolic blood pressure (SBP) was controlled to less than 120 mmHg during the acute phase. After that, in the chronic phase, we attempted to control SBP to less than 140 mmHg and diastolic blood pressure (DBP) to less than 90 mmHg.
All patients underwent coronary angiography immediately after admission. They received reperfusion therapy, including percutaneous transluminal coronary revascularization (PTCR), plain old balloon angioplasty (POBA), and percutaneous transluminal coronary stent implantation. Reperfusion therapy was considered successful when the coronary flow with the culprit lesion attained a TIMI flow grade of 3. After reperfusion therapy, all subjects underwent left ventriculography (LVG). Right anterior oblique 30° views of LVG were used for assessment of regional and global LV function. LV end-diastolic and LV end-systolic volumes (EDV, ESV), and LV ejection fraction (EF) were measured according to the area-length method. LVG was performed again 6 months after the occurrence of MI, and EDV, ESV, and EF were measured by the same method. None of the patients had residual ischemia after coronary intervention or before admission.
Clinical Data and Outcomes
Patients were divided into two groups on the basis of blood pressure at the examination before their MI. Normotensive patients (normotensive group) had an SBP less than 140 mmHg and a DBP less than 90 mmHg, and were not current users of antihypertensive drugs. Hypertensive patients (hypertensive group) had an SBP of 140 mmHg or more or a DBP of 90 mmHg or more, or were current users of antihypertensive drugs. Patients with hypertension commenced treatment with antihypertensive drugs immediately after admission. End-diastolic volume index (EDVI), end-systolic volume index (ESVI), and EF were compared between the acute phase and 6 months after MI in each group. The percent changes in EDVI, ESVI, and EF were also compared between the two groups. The percent change of a value A was defined as: 100 × (value of A at 6 months after MI -value of A at acute phase) / value of A at acute phase. An increase > 15% in the LV EDVI or LV ESVI after revascularization was defined as ongoing LV remodeling (11).
Statistical Analysis
Values are expressed as the mean±SD. Categorical variables were analyzed by the χ 2 test. Continuous variables were analyzed by unpaired or paired t-test. All variables entered the multivariable stage, regardless of the results of univariable analyses. Multivariable regression was then performed by stepwise backward deletion. All variables with a probability value < 0.25 remained in the final model. Values of p< 0.05 were considered to indicate statistical significance.
Results
The study sample consisted of 94 patients who met all inclusion criteria. Baseline, clinical and procedural characteristics of the study group are listed in Table 1 . Compared with the normotensive group, the hypertensive group had a higher percentage of males, higher incidence of diabetes mellitus, and greater frequency of use of calcium channel blockers.
LV parameters at acute phase and at the 6-month follow-up are summarized in Table 2 . EDVI, ESVI, and EF were similar between the hypertensive group and the normotensive group both at the acute phase and the 6-month follow-up. However, changes in these parameters differed between the two groups over this 6-month period.
There were significant increases in both EDVI and ESVI in the hypertensive group after 6 months (67.4±17.0 to 76.2±23.7, p< 0.001; and 26.3±12.5 to 32.0±8.7, p= 0.01, respectively), whereas there were no significant increases in the normotensive group (69.8±16.1 to 72.4±16.6, p= NS; and 30.3±12.2 to 28.6±16.4, p= NS, respectively). In addition, EF in the hypertensive group did not change (61.2±12.4 to 59.8±13.4, p= NS), whereas EF in the normotensive group increased significantly after 6 months (56.7±14.0 to 61.9±14.1, p< 0.01). As a result, there were significant differences in the percent change in ESVI and EF between the hypertensive group and the normotensive group, whereas there was no significant difference in the percent change in EDVI between the two groups.
In this study, the blood pressure was controlled at under 140/90 mmHg. For 1 week after acute MI, we kept the blood pressure under 120 mmHg because we had to prevent cardiac rupture. At 2 months after MI, the SBP values in antecedent patients and normotensive patients were 121±8 mmHg and 137±8 mmHg (p< 0.05). At 2 months after MI, the DBP values in antecedent patients and normotensive patients were 71±8 mmHg and 87±7 mmHg (p< 0.05). At 6 months after MI, the blood pressure in hypertensive patients was significantly higher than in normotensive patients. Heart rate was not different between the two groups. Table 3 shows the predictors of LV remodeling after revascularization. Hypertension was both a univariable (p= 0.008) and a multivariable predictor of LV remodeling (odds ratio [OR]: 0.94; 95% confidence interval [CI]: 0.879 to 1.004; p= 0.0159). ACE inhibitors and calcium channel blockers were also both univariable and multivariable predictors of LV remodeling.
The baseline, clinical and procedural characteristics of the study group with blood pressure-matched patients are listed in Table 4 . LV parameters at acute phase and at the 6-month follow-up are summarized in Table 5 . EDVI, ESVI, and EF were similar between the hypertensive group and the normotensive group both at the acute phase and at 6 months of follow-up. As a result, there were no significant differences between the hypertensive group with blood pressure-matched patients and the normotensive group.
Discussion
Hypertension is a well-established risk factor for coronary artery disease and acute MI (12, 13) . Effects of chronic hypertension, which may negatively affect outcomes after acute MI, include increased coronary vascular resistance, decreased coronary reserve, pre-existing muscle fiber hyperplasia and augmented interstitial collagen together with possible alterations in the responsiveness of the coronary vasculature to vasoactive transmitters (14, 15) . Hypertension is also a common substrate for heart failure (16, 17) , which has a high mortality (18) . In those with antecedent hypertension, we found increased LV cavity after MI. Our most important finding is that hypertension was both a univariable predictor and a multivariable predictor of LV remodeling. We suppose that the antecedent hypertension may play an important role in stimulating the LV remodeling after MI. LV remodeling is a process by which ventricular size, shape, and function are regulated by mechanical, neurohormonal, and genetic factors (19−21) . Remodeling may be physiological and adaptive during normal growth or pathological due to MI, cardiomyopathy, hypertension, or valvular heart disease. The acute loss of myocardium results in an abrupt increase in loading conditions that induces a unique pattern of remodeling involving the infarcted border zone and remote noninfarcted myocardium. Ventricular remodeling may continue for weeks or months until the distending forces are counterbalanced by the tensile strength of the collagen scar. This balance is determined by the size, location, and transmurality of the infarct, the extent of myocardial stunning, the patency of the infarct-related artery, local tropic factors and mechanical stress (19, 20) . In this study, the blood pressure was controlled at under 140/90 mmHg. For 1 week after acute MI, we kept the blood pressure under 120 mmHg because we had to prevent cardiac rupture. After discharge, the blood pressure in antecedent hypertensive patients might have been higher than that in normotensive patients. This difference may affect the LV remodeling after MI.
Recent outcome trials have examined and continued to investigate the benefits associated with different levels of blood pressure control or have compared several of the "newer" classes of antihypertensive drugs (22−24). Staessen et al. performed a meta-regression analysis of 30 clinical trials that included a total of 149,407 patients (25) . They based their analysis on summary statistics reported in the literature, and showed that blood pressure gradients accounted for most, if not all, of the differences in outcome in patients with hypertension or patients at high cardiovascular risk. They conducted a study in patients with isolated systolic hypertension and showed that antihypertensive drug treatment reduced the risk of stroke and all cardiovascular complications. They emphasized the desirability of tight blood pressure control. Thus, to achieve risk reduction in hypertensive patients, we may have to decrease blood pressure more strictly after MI.
In 1992, with the publication of the Survival and Ventricular Enlargement (SAVE) trial, angiotensin converting (27) . There is now unequivocal evidence from randomized, placebo-controlled mortality trials that ACE inhibitors reduce the rate of mortality from STEMI. These trials can be grouped into two categories. The first consists of trials that included only selected myocardial patients who showed features indicative of increased mortality, such as LV EF of less than 40%, clinical signs and symptoms of congestive heart failure (28), anterior location of infarction (29) , and abnormal wall motion score index (30) . The second group consists of unselective trials that randomized all patients with MI provided they had a minimum systolic pressure of approximately 100 mmHg (ISIS-4 (31) , GISSI-3 (28), and CONSENSUS II (32)). A consistent survival benefit was observed in ISIS-4 and GISSI-3, but not in CONSENSUS II. In our study, EF was about 60% and the myocardial damage was small. In this ISIS-4 study, no benefit was observed in patients without ST elevation. Short-term ACE inhibition does not appear to confer any benefit for patients with non-ST elevation myocardial infarction (NSTEMI). On the other hand, long-term use of ACE inhibition is beneficial in preventing recurrent ischemic events and mortality in a broad population of patients now including those with any evidence of coronary artery disease (33, 34) . It is of note that recurrent MI and the need for revascularization were reduced with captopril and enalapril in the SAVE (26) and Studies of Left Ventricular Dysfunction (SOLVD) trials (35) , which has now been confirmed using ramioril and perindopril in the Heart Outcomes Prevention Evaluation (HOPE) (33) and European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) (34) , suggesting an antiischemic effect of this entire class of agents. However, the PEACE study recently reached a different conclusion (36) . In patients with stable coronary artery disease and preserved LV function who are receiving current standard therapy, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of preventing death from cardiovascular causes, MI, or coronary revascularization. Therefore, it remains a matter of controversy whether ACE inhibitors should be administered to patients with acute MI with minimal myocardial damage.
Study Limitations
Because echocardiographic follow-up was not performed after revascularization, cardiac hypertrophy and cardiac weights could not be estimated. Both of these parameters are important in LV remodeling, and echocardiographic examination is an excellent method to determine the cardiac morphology and function non-invasively and repeatedly. In a future study, we will try to use echocardiography to examine the remodeling process more precisely. In summary, our results showed that antecedent hypertension may have a deleterious effect on LV remodeling after MI.
